Vir Biotechnology, Inc.
VIR
Rank in Stocks
#5459
Vir Biotechnology, Inc. operates as an immunology company with commercialized... Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases. Its pipeline features several key candidates: Sotrovimab (branded as Xevudy, or VIR-7832), a neutralizing monoclonal antibody for both treating and preventing SARS-CoV-2 infection; VIR-2218 and VIR-3434, aimed at hepatitis B virus; VIR-2482, targeting the prevention of influenza A virus; and VIR-1111, designed to prevent human immunodeficiency virus. The firm maintains a robust network of strategic partnerships and collaborations. These include grant support from organizations like the Bill & Melinda Gates Foundation and the National Institutes of Health. It holds option and licensing arrangements with entities such as Brii Biosciences Limited, and a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. Further licensing relationships exist with The Rockefeller University and MedImmune, Inc. Collaborations extend to WuXi Biologics and Glaxo Wellcome UK Ltd., alongside a research agreement with GlaxoSmithKline Biologicals SA. Furthermore, Vir has secured a manufacturing contract with Samsung Biologics Co.,Ltd. for SARS-CoV-2 antibodies and a clinical development partnership with Gilead Sciences, Inc. focused on chronic hepatitis B virus. The company, established in 2016, is headquartered in San Francisco, California.
Share Price
$13.65
Last synced: 2026-11-09
Market Cap
$2.31B
Change (1 day)
11.75%
Change (1 year)
138.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vir Biotechnology, Inc. (VIR)
Category
Healthcare
EPS for Vir Biotechnology, Inc. (VIR)
EPS as of September 2026 TTM: $-1.25
According to Vir Biotechnology, Inc.'s latest financial reports, its current EPS (TTM) is $-1.25. At the end of 2025 the company had an EPS of $-3.16, an increase over its 2024 EPS of $-3.83.
EPS history for Vir Biotechnology, Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.25 | -60.44% |
| 2025 | $-3.16 | -17.49% |
| 2024 | $-3.83 | -16.56% |
| 2023 | $-4.59 | -217.99% |
| 2022 | $3.89 | -4.42% |
| 2021 | $4.07 | -262.15% |
| 2020 | $-2.51 | 54.94% |
| 2019 | $-1.62 | 35.00% |
| 2018 | $-1.20 | -88.02% |
| 2017 | $-10.02 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,352.80% |
US
|
|
| $-7.07 | 465.60% |
US
|
|
| $-5.29 | 323.20% |
AU
|
|
| $12.88 | -1,130.41% |
BE
|
|
| $21.56 | -1,824.80% |
NL
|
Questions about Vir Biotechnology, Inc.'s earnings per share (EPS)
What is Vir Biotechnology, Inc.'s earnings per share (EPS)?
Vir Biotechnology, Inc.'s earnings per share (EPS) over the last twelve months is $-1.25, as of Sep 2026.
What was Vir Biotechnology, Inc.'s earnings per share (EPS) in 2025?
In 2025, Vir Biotechnology, Inc.'s earnings per share (EPS) was $-3.16, compared with $-3.83 in 2024.
How has Vir Biotechnology, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Vir Biotechnology, Inc.'s earnings per share (EPS) was highest in 2021 ($4.07) and lowest in 2023 ($-4.59).
How does Vir Biotechnology, Inc.'s earnings per share (EPS) compare with similar companies?
Vir Biotechnology, Inc.'s earnings per share (EPS) ($-1.25) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.